Santaris Pharma to raise EUR 12.5m
Hamburg – Santaris Pharma A/S aims to close a Serie C financing round valued at a12.5 million in November/December. As the company announced during its pre-sentation in the framework of the BioEurope partnering conference held in Hamburg, Germany, from 12th to 14th October, negotiations with four investors are ongoing. Horsholm-based company Santaris Pharma was established in 2003 through the merger of the two biotech companies Pantheco A/S and Cureon A/S. The major focus of the company is to develop drug candidates based on Locked Nucleic Acid (LNA). One of the lead products (spc2996) is an Bcl-2 mRNA antagonist for the treatment of chronic lymphocytic leukaemia, with which an optimised second phase I/II began in Q1 2007. In 2006, the company raised a40 million.